1. Home
  2. DARE vs KYNB Comparison

DARE vs KYNB Comparison

Compare DARE & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dare Bioscience Inc.

DARE

Dare Bioscience Inc.

HOLD

Current Price

$1.34

Market Cap

19.2M

Sector

Health Care

ML Signal

HOLD

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$7.05

Market Cap

27.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DARE
KYNB
Founded
2015
1993
Country
United States
United States
Employees
24
34
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.2M
27.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
DARE
KYNB
Price
$1.34
$7.05
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
188.8K
10.9K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,807,885.00
N/A
Revenue This Year
$2,115.12
N/A
Revenue Next Year
$122.62
N/A
P/E Ratio
N/A
$0.15
Revenue Growth
N/A
N/A
52 Week Low
$1.16
$6.32
52 Week High
$3.78
$9.58

Technical Indicators

Market Signals
Indicator
DARE
KYNB
Relative Strength Index (RSI) 26.82 48.13
Support Level N/A $7.04
Resistance Level $1.84 $7.37
Average True Range (ATR) 0.13 0.24
MACD -0.07 -0.05
Stochastic Oscillator 16.33 15.49

Price Performance

Historical Comparison
DARE
KYNB

About DARE Dare Bioscience Inc.

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Share on Social Networks: